title: Bromocriptine treatment in a murine Parkinson's model: ultrastructural evaluation after dopaminergic deafferentation.
abstract: The objective of this article was to identify the effects of bromocriptine on the ultrastructure of the caudate nucleus in rats with a 6-hydroxidopamine (6-OHDA) unilateral lesion of the substantia nigra pars compacta. Eighteen Wistar male rats were stereotactically lesioned with 6-OHDA (n=12), or sham lesioned (n=6). Two days after rotational behavior was tested, and 2 days later, 6 rats were treated with 0.3 mg/Kg bromocriptine orally for a month and 6 rats were kept for the same time without treatment. The neuropile of the sham operated and bromocriptine-treated rats was well preserved contrary to the non-bromocriptine-treated rats. Also, it was found that there was a significant difference in the number of synaptic endings with edema in caudate of bromocriptine-treated rats compared with non-treated rats; however, the size of the synaptic endings were different to those found in the sham lesioned rats. Also, as in the sham lesioned group, the bromocriptines showed more synaptic contacts with dendritic spines contrasting to the non-treated group. The results suggest that bromocriptine possesses antioxidant properties because it decreased the ultrastructural alterations after 6-OHDA lesion.
authors: Department of Neuroscience, National University of Mexico, Iztacala, Mexico. nigraizo@servidor.unam.mx
authors: María Rosa
authors: MR
authors: Avila-Costa
authors: Laura
authors: L
authors: Colín-Barenque
authors: Enrique
authors: E
authors: Montiel-Flores
authors: Patricia
authors: P
authors: Aley-Medina
authors: Ana Luisa Gutiérrez
authors: AL
authors: Valdez
authors: José Luis Ordóñez
authors: JL
authors: Librado
authors: Erick Flores
authors: EF
authors: Martínez
authors: Verónica Anaya
authors: VA
authors: Martínez
authors: Patricia
authors: P
authors: Mussali-Galante
authors: Teresa I
authors: TI
authors: Fortoul
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D002421:Caudate Nucleus / Q000378:metabolism* / Q000648:ultrastructure*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D009045:Motor Endplate / Q000378:metabolism / Q000648:ultrastructure; D018384:Oxidative Stress / Q000502:physiology; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000978:Antiparkinson Agents; D001971:Bromocriptine; D004298:Dopamine